A new pocket for D4
Crystal structure paves way to dopamine D4 receptor-selective agonists
The early promise of the dopamine D4 receptor as a therapeutic target for psychiatric disorders hasn’t been borne out because of the difficulty of producing sufficiently selective compounds. Last month in Science, a collaboration between UNC Chapel Hill and UCSF united crystallography and in silico drug discovery to find a selective D4 agonist that could spur new cognitive therapies.
The study was led by Bryan Roth, a pharmacology professor at University of North Carolina at Chapel Hill, and Brian Shoichet, a pharmacy professor at the University of California San Francisco, who teamed up to use Roth’s expertise in protein expression and crystallography and Shoichet’s in silico drug screening expertise. ...
BCIQ Company Profiles
BCIQ Target Profiles